BiotechTube
Veraxa Biotech

Veraxa Biotech

Munich, Germany· Est.
veraxa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Veraxa Biotech is a private, preclinical-stage biotech company developing next-generation antibody-based cancer therapeutics. Its core technology platform includes proprietary BiTAC (bispecific T cell engager) and advanced ADC (antibody-drug conjugate) technologies, aimed at creating safer and more effective treatments. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), the company is led by an experienced management team with backgrounds in drug development, venture capital, and major biopharma firms like Amgen and Harpoon Therapeutics. Veraxa is advancing a pipeline of novel candidates, with its lead program in clinical studies for AML.

Oncology

Technology Platform

Integrated suite for next-generation antibody therapeutics, including the proprietary BiTAC (Bispecific T cell engager Antibody Conjugate) platform, next-generation ADC technologies, and functional antibody screening.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The large and growing market for targeted cancer therapies, especially ADCs and T cell engagers, presents a significant opportunity.
Veraxa's novel BiTAC format, which combines these two modalities, could address unmet needs in difficult-to-treat cancers and capture value in this high-innovation segment.
Successful clinical validation could lead to lucrative partnerships or acquisition interest from large pharmaceutical companies.

Risk Factors

The primary risks include clinical failure of the novel and unproven BiTAC technology, the high cash burn rate requiring continual fundraising in a challenging financial environment, and intense competition from numerous well-funded players in the ADC and bispecific antibody space.
Manufacturing complexities for such advanced biologics also pose a significant technical and operational risk.

Competitive Landscape

Veraxa operates in the highly competitive fields of ADC and T cell engager development, competing against large pharmaceutical companies (e.g., AstraZeneca, Pfizer, Roche) and numerous biotechs. Its differentiation relies on the novelty of its combined BiTAC format. Success will depend on demonstrating superior efficacy or safety profiles compared to established and next-generation single-mechanism agents.

More companies in Biologics / Biosimilars →More companies in Germany →